Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 24, 2018

Impact of adipose tissue on prostate cancer aggressiveness – analysis of a high-risk population

Guila Delouya , David Tiberi , Sahir R. Bhatnagar , Shanie Campeau , Fred Saad and Daniel Taussky EMAIL logo



We investigated whether visceral adiposity is associated with more aggressive disease at prostatectomy.

Materials and methods

Four hundred and seventy-four patients referred for postoperative adjuvant or salvage radiotherapy were included in this study. Primary endpoints were positive surgical margins (pSM) or extracapsular extension (ECE). Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were manually contoured. Univariate and multivariate logistic regression was performed.


In univariate analysis, VAT volume (p = 0.006), adipose tissue ratio (VAT/SAT, p = 0.003), density of the SAT (p = 0.04), as well as age (p < 0.001) were associated with pSM. In the univariate analysis, SAT density was associated with a trend towards a higher rate of ECE (p = 0.051) but visceral fat volume (p = 0.01), as well as the adipose tissue ratio (p = 0.03) were both protective factors. None of the adipose tissue measurements or BMI had an influence on biochemical recurrence or overall survival (all p ≥ 0.5).


SAT-volume and increased SAT-density were generally associated with more aggressive prostate cancers whereas VAT as a protective factor. These findings emphasize a possible mechanism for the association between obesity and prostate cancer aggressiveness.

Author Statement

  1. Research funding: Authors state no funding involved.

  2. Conflict of interest: Authors state no conflict of interest.

  3. Informed consent: For this retrospective study no informed consent was necessary.

  4. Ethical approval: Local ethics board approval was obtained.


[1] Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer – viewpoint of the IARC working group. N Engl J Med. 2016;375:794–8.10.1056/NEJMsr1606602Search in Google Scholar

[2] Litwin SE. Good fat, bad fat: the increasingly complex interplay of adipose tissue and the cardiovascular system. J Am Coll Cardiol. 2013;62:136–7.10.1016/j.jacc.2013.04.028Search in Google Scholar

[3] Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC, Jenkins JT. The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review. Eur J Surg Oncol. 2015;41:186–96.10.1016/j.ejso.2014.10.056Search in Google Scholar

[4] Rickles AS, Iannuzzi JC, Mironov O, Deeb AP, Sharma A, Fleming FJ, et al. Visceral obesity and colorectal cancer: are we missing the boat with BMI? J Gastrointest Surg. 2013;17:133–43; discussion p 143.10.1007/s11605-012-2045-9Search in Google Scholar

[5] Cakir H, Heus C, van der Ploeg TJ, Houdijk AP. Visceral obesity determined by CT scan and outcomes after colorectal surgery; a systematic review and meta-analysis. Int J Colorectal Dis. 2015;30:875–82.10.1007/s00384-015-2174-1Search in Google Scholar

[6] Vidal A, Howard L, Sun S, Cooperberg M, Kane C, Aronson WJ, et al. Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Prostate Cancer Prostatic Dis. 2016;20:72–8.10.1038/pcan.2016.47Search in Google Scholar

[7] Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22:446–53.10.1200/JCO.2004.04.181Search in Google Scholar

[8] Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC Jr, et al. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology. 2007;69:495–9.10.1016/j.urology.2006.10.036Search in Google Scholar

[9] Zilli T, Chagnon M, Van Nguyen T, Bahary JP, Guay JP, Dufresne A, et al. Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic findings in patients treated with radiotherapy for localized prostate cancer. Cancer. 2010;116:5650–8.10.1002/cncr.25539Search in Google Scholar

[10] Zilli T, Nguyen T, Bahary J, Chagnon M, Dufresne A, Taussky D. Prognostic impact of abdominal adiposity, waist circumference and body mass index in patients with intermediate-risk prostate cancer treated with radiotherapy. Int J Obes. 2011;35:1421–6.10.1038/ijo.2010.279Search in Google Scholar

[11] Nattenmueller J, Hoegenauer H, Boehm J, Scherer D, Paskow M, Gigic B, et al. CT-based compartmental quantification of adipose tissue versus body metrics in colorectal cancer patients. Eur Radiol. 2016;26:4131–40.10.1007/s00330-016-4231-8Search in Google Scholar

[12] Mano R, Hakimi AA, Zabor EC, Bury MA, Donati OF, Karlo CA, et al. Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma. Can Urol Assoc J. 2014;8:E675–80.10.5489/cuaj.1979Search in Google Scholar

[13] Balentine CJ, Marshall C, Robinson C, Wilks J, Anaya D, Albo D, et al. Validating quantitative obesity measurements in colorectal cancer patients. J Surg Res. 2010;164:18–22.10.1016/j.jss.2010.05.048Search in Google Scholar

[14] Murphy RA, Register TC, Shively CA, Carr JJ, Ge Y, Heilbrun ME, et al. Adipose tissue density, a novel biomarker predicting mortality risk in older adults. J Gerontol A Biol Sci Med Sci. 2014;69:109–17.10.1093/gerona/glt070Search in Google Scholar

[15] Alvey NJ, Pedley A, Rosenquist KJ, Massaro JM, O’Donnell CJ, Hoffmann U, et al. Association of fat density with subclinical atherosclerosis. J Am Heart Assoc. 2014:3.10.1161/JAHA.114.000788Search in Google Scholar

[16] Veld J, Vossen JA, De Amorim Bernstein K, Halpern EF, Torriani M, Bredella MA. Adipose tissue and muscle attenuation as novel biomarkers predicting mortality in patients with extremity sarcomas. Eur Radiol. 2016;26:4649–55.10.1007/s00330-016-4306-6Search in Google Scholar

[17] Rosenquist KJ, Pedley A, Massaro JM, Therkelsen KE, Murabito JM, Hoffmann U, et al. Visceral and subcutaneous fat quality and cardiometabolic risk. JACC Cardiovasc Imaging. 2013;6:762–71.10.1016/j.jcmg.2012.11.021Search in Google Scholar

[18] Zimmermann M, Delouya G, Barkati M, Campeau S, Rompotinos D, Taussky D. Impact of visceral fat volume and fat density on biochemical outcome after radical prostatectomy and postoperative radiotherapy. Horm Mol Biol Clin Investig. 2016;26:173–8.10.1515/hmbci-2015-0075Search in Google Scholar

[19] Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol. 2016;34:3655–63.10.1200/JCO.2016.66.7311Search in Google Scholar

[20] Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit JM, Guiu S, et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist. 2011;16:71–81.10.1634/theoncologist.2010-0227Search in Google Scholar

[21] Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J Clin Oncol. 2016;34:4270–6.10.1200/JCO.2016.67.4283Search in Google Scholar

[22] Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460–8.10.1016/0002-9149(94)90676-9Search in Google Scholar

[23] Festa A, D’Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord. 2001;25:1407–15.10.1038/sj.ijo.0801792Search in Google Scholar

[24] Von Hafe P, Pina F, Pérez A, Tavares M, Barros H. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res. 2004;12:1930–5.10.1038/oby.2004.242Search in Google Scholar

[25] Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol. 2009;182:1621–7.10.1016/j.juro.2009.06.015Search in Google Scholar

[26] Taussky D, Barkati M, Campeau S, Zerouali K, Nadiri A, Saad F, et al. Changes in periprostatic adipose tissue induced by 5α‐reductase inhibitors. Andrology. 2017;5:511–5.10.1111/andr.12331Search in Google Scholar

[27] Iyengar NM, Zhou XK, Gucalp A, Morris PG, Howe LR, Giri DD, et al. Systemic correlates of white adipose tissue inflammation in early-stage breast cancer. Clin Cancer Res. 2016;22:2283–9.10.1158/1078-0432.CCR-15-2239Search in Google Scholar

[28] Iyengar NM, Ghossein RA, Morris LG, Zhou XK, Kochhar A, Morris PG, et al. White adipose tissue inflammation and cancer‐specific survival in patients with squamous cell carcinoma of the oral tongue. Cancer. 2016;122:3794–802.10.1002/cncr.30251Search in Google Scholar

[29] Ellem SJ, Risbridger GP. Aromatase and regulating the estrogen: androgen ratio in the prostate gland. J Steroid Biochem Mol Biol. 2010;118:246–51.10.1016/j.jsbmb.2009.10.015Search in Google Scholar

Received: 2018-07-06
Accepted: 2018-09-11
Published Online: 2018-11-24

©2018 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 4.12.2022 from
Scroll Up Arrow